In this video, health-care analyst David Williamson discusses the briefing documents recently released by the FDA in advance of Delcath Systems and Aveo Pharmaceuticals advisory committee meetings. They range from damaging to devastating.

Watch and find out what sent shares of the two companies plummeting down 40% and 30% respectively and whether the sell-offs were deserved.